BRAF and colorectal carcinoma: Furthermore, mutations in BRAF, TP53, or SMAD4 significantly reduced the progression-free survival of patients with colorectal carcinoma (p = 4.24 × 10−4) but were not correlated with overall survival (p = 0.27; Figure 5F,G).